Monday 19 September 2016

Ten biomarkers predict cardiac outcomes in patients with diabetes

Ten biomarkers predict cardiac outcomes in patients with diabetes Ten biomarkers have been identified that predicted cardiac outcomes in high-risk patients with diabetes. These 10 biomarkers were earlier identified in the ORIGIN trial (Outcome Reduction with an Initial Glargine Intervention) published in 2015 in the journal Circulation and now have shown the ability to similarly predict cardiovascular events in patients with diabetes in the HOPE trial (Heart Outcomes Prevention Evaluation) in addition to the usual clinical risk factors The biomarker panel includes 1. N-terminal pro-B-type natriuretic peptide (NT-proBNP) 2. Trefoil factor 3 3. Growth/differentiation factor 15 4. Apolipoprotein B 5. Angiopoietin-2 6. Osteoprotegerin 7. α-2-macroglobulin 8. Hepatocyte growth factor receptor 9. Glutathione S transferase α 10. Chromogranin A The findings were presented (Abstracts 58, 60) at the European Association for the Study of Diabetes (EASD) 2016 Annual Meeting, which concludes in Munich, Germany today. Presenting the findings, the lead investigator, Hertzel Gerstein, MD, from McMaster University, Hamilton, Ontario said, "The biomarkers do not replace the clinical risk factors but…they enhance and improve prediction of cardiovascular events, over and above using clinical risk factors alone." (Source: Medscape)

No comments:

Post a Comment